Navigation Links
Scripps Research Institute Scientists Develop Alternative to Gene Therapy
Date:7/1/2012

LA JOLLA, CA July 1, 2012 Scientists at The Scripps Research Institute have discovered a surprisingly simple and safe method to disrupt specific genes within cells. The scientists highlighted the medical potential of the new technique by demonstrating its use as a safer alternative to an experimental gene therapy against HIV infection.

"We showed that we can modify the genomes of cells without the troubles that have long been linked to traditional gene therapy techniques," said the study's senior author Carlos F. Barbas III, who is the Janet and Keith Kellogg II Professor of Molecular Biology and Chemistry at The Scripps Research Institute.

The new technique, reported in Nature Methods on July 1, 2012, employs zinc finger nuclease (ZFN) proteins, which can bind and cut DNA at precisely defined locations in the genome. ZFNs are coming into widespread use in scientific experiments and potential disease treatments, but typically are delivered into cells using potentially risky gene therapy methods.

The Scripps Research scientists simply added ZFN proteins directly to cells in a lab dish and found that the proteins crossed into the cells and performed their gene-cutting functions with high efficiency and minimal collateral damage.

"This work removes a major bottleneck in the efficient use of ZFN proteins as a gene therapy tool in humans," said Michael K. Reddy, who oversees transcription mechanism grants at the National Institutes of Health's (NIH) National Institute of General Medical Sciences, which helped fund the work, along with an NIH Director's Pioneer Award. "The directness of Dr. Barbas's approach of 'simply' testing the notion that ZFNs could possess an intrinsic cell-penetrating ability is a testament to his highly creative nature and further validates his selection as a 2010 recipient of an NIH Director's Pioneer Award."

Questioning Assumptions

ZFNs, invented in the mid-1990s,
'/>"/>

Contact: Mika OnoScripps Research Institute scientists develop alternative to gene therapy
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Scripps Research Institute announces five-year research collaboration with Bristol-Myers Squibb
2. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
3. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
4. Plastic trash altering ocean habitats, Scripps study shows
5. Scripps Florida scientists identify neurotranmitters that lead to forgetting
6. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
7. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
8. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
9. Scripps Research Institute scientists develop antidote for cocaine overdose
10. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
11. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research Institute Scientists Develop Alternative to Gene Therapy
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... the United States is in danger of coming to ... the requirement whether existing or anticipated to ... gas. But an MIT analysis suggests an intermediate step ... to fend off growing electricity shortages using our most-abundant, ...
... "chip" or array that can quickly detect disorders such as ... an effective tool in prenatal diagnosis in a series of ... a report that appears in the current issue of the ... team led by Dr. Arthur Beaudet and Dr. Sau Wai ...
... a relationship between two proteins in the brain that has ... led to speculation that existing drugs used to curb nicotine ... alleviate the symptoms of autism. The discovery identified a ... which is located in brain cells and assists in connecting ...
Cached Biology News:MIT: A quicker, easier way to make coal cleaner 2MIT: A quicker, easier way to make coal cleaner 3Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3Researchers find link between nicotine addiction and autism 2Researchers find link between nicotine addiction and autism 3
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... 18 /Xinhua-PRNewswire/ -- Today, NovaSecta,Sundia Meditech and ... drug discovery solutions for European pharmaceutical and ... quality scientific,capabilities of Sundia and HD BioSciences ... of European mid-sized pharmaceutical and,biotech companies., ...
... Much of the work in MIT Institute Professor Robert ... of science fiction, but its products are already saving lives ... of Langers specialties is growing the vital tissues of the ... such as the liver and intestinesin a laboratory dish instead ...
... Conn., Feb. 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ... February 15, 2008 on its 7.75% Convertible Senior Notes,due ... Notes is $60,million., The Company paid $2,376,666.67 through ... $2,376,345.60 was paid in 5,500,800,shares of Common Stock, based ...
Cached Biology Technology:European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions 2European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions 3MIT researcher addresses biomedical engineering challenges 2MIT researcher addresses biomedical engineering challenges 3Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2
... The Infinite 200 series of microplate ... or absorbance detection in an affordable, easy-to-use ... science applications. The unique modular design and ... researchers with a choice of a monochromator ...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Biology Products: